{"entity":{"id":"paper-kim-anticancer-pricing-reimbursement-korea-erpor-2021","kind":"paper","name":"Trends in the pricing and reimbursement of new anticancer drugs in South Korea","aka":[],"tldr":"Thirty-two new cancer drugs reviewed in Korea between 2017 and 2020 took on average 36.7 months to reach the insurance list, and the drugs listed at lower prices relative to other countries were listed faster.","summary":"Anticancer drugs among new drugs reviewed between January 2017 and March 2020 were analysed for reimbursement coverage, time to listing and listing price after the introduction of alternative pricing and reimbursement pathways. Thirty-two drugs were included. Average time to listing was 36.7 months. The listing price was 12.6 to 90.2 per cent of the average adjusted price in seven reference countries, and the ratio of listing price to the external reference price correlated with time to listing (Pearson r -0.37, p 0.035).","asOf":"2026-11-03","links":[{"label":"Expert Rev Pharmacoecon Outcomes Res 2021","url":"https://doi.org/10.1080/14737167.2021.1860023"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/33275463/"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["hira"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"journal":"Expert Review of Pharmacoeconomics and Outcomes Research","year":2021,"doi":"10.1080/14737167.2021.1860023","pmid":"33275463","authors":"Kim S, Kim J, Cho H, Lee K, Ryu C, Lee JH","paperType":"observational","findings":["Average time to listing 36.7 months for 32 anticancer drugs reviewed 2017 to 2020.","Listing price 12.6 to 90.2 per cent of the seven-country adjusted average.","Lower relative price correlated with faster listing (r -0.37, p 0.035)."],"whatItMeans":"In this period a new cancer drug typically took about three years after approval to be covered by Korean insurance, and the faster route was a lower price.","caveats":["Time to listing measured for drugs that were listed; drugs never listed are outside the average.","The period precedes the 2024 rule changes on flexible thresholds."],"participants":32},"route":"/key-papers/paper-kim-anticancer-pricing-reimbursement-korea-erpor-2021/","neighbours":{"institution":[{"id":"hira","kind":"institution","name":"Health Insurance Review and Assessment Service (HIRA)","route":"/institutions/hira/"}]}}